NXTC News and Press, NextCure Inc. From 12/21/23

BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a ma...

2023-12-14 14:28:36 ET More on NextCure Seeking Alpha’s Quant Rating on NextCure Historical earnings data for NextCure Financial information for NextCure For further details see: NextCure stock falls 20% amid program shutdown, business update

2023-12-14 12:28:56 ET Gainers: Freight Technologies ( FRGT ) +178% . TPI Composites ( TPIC ) +67% . TriSalus Life Sciences ( TLSI ) +35% . Codexis ( CDXS ) +33% . Canterbury Park Holding Corp ( CPHC ) +33% . Canaan ( CAN ...

2023-12-14 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Ocular Therape...

2023-12-14 08:23:30 ET More on Pre-market losers & stocks. Cepton, Inc. (CPTN) Q3 2023 Earnings Call Transcript Shattuck Labs, Inc. (STTK) Q3 2023 Earnings Call Transcript Shattuck Labs, Inc. 2023 Q3 - Results - Earnings Call Presentation Shattuck Labs st...

BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinica...

BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participat...

New publication in Journal of Clinical Investigation provides compelling evidence for NC525’s ability to specifically kill leukemic cells while sparing healthy cells in non-clinical modeling Update for ongoing Phase 1a clinical trial is expected in the fourth quarter of 2023 ...

2023-11-02 17:53:16 ET More on NextCure Seeking Alpha’s Quant Rating on NextCure Historical earnings data for NextCure Financial information for NextCure For further details see: NextCure GAAP EPS of -$0.51

Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year end Cash of approximately $118 million expected to fund operations into mid-2025 BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-st...